Web Analytics
ERAS (NASDAQ) Stock Analysis | ERASCA INC – Deepscope
MARKET

Select Market Data Region

ERAS — ERASCA INC (Healthcare >> Biotechnology)

ERAS FAQ

What is ERAS's ROE?

ERASCA INC reports a Return on Equity (ROE) of -70.39%.

What is ERAS's dividend yield?

ERASCA INC offers a dividend yield of 0.00%.

What is ERAS's Deepscope Quality Score?

Deepscope rates ERAS's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ERAS?

Deepscope's AI Timing Score for ERAS is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ERAS belong to?

ERASCA INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

Stock Check   *Daily update data at 9:30 AM*
(Price: 2026-06-05 | FS: 2026-03-31)

ERAS

ERASCA INC
USD 11.97
-1.30 (-9.80%) Day Change
0.01
D/E
-70.4%
ROE
-60.1%
ROA
0.00%
Div Yield
USD 11.97
Price
-1.30 (-9.80%)
Day Change
NEWS SCORE: 82

ERAS, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

38

QUALITY

Signal
UNDERPERFORM
Signal Description
Company financial health is Not Good
Reason
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors 45%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 82
  Magic Formula Rank by ROA
N/A
  Magic Formula Rank by ROE
N/A
  Magic Formula Rank by ROIC
N/A
  Price 11.97
  PBV / Sector
10.49 / 4.63
  Earning Per Share -0.80
  PE / Sector
N/A / 17.43
  PEG or PE/Growth / Sector
N/A / 0.53
  Average 1M Daily Value
55.77 M
  Average 1W Daily Value
91.99 M
Timing Factors 42%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
Financial Health 45%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
Ability to Make Profit 37%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
N/A / 449.48
  NPM Average (%) / Sector
N/A / -1,506.49
  NPM Change Average (%) / Sector
N/A / 4,940.99
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
-60.06 / 30.58
  ROA Average (%) / Sector
-40.49 / -347.17
  ROA Change Average (%) / Sector
14.39 / 5,125.52
GOOD
  ROE (%) / Sector
-70.39 / -3.58
  ROE Average (%) / Sector
-49.06 / 40.65
  ROE Change Average (%) / Sector
11.94 / 2,109.80
GOOD
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
Return to Investors 4%
X
  Dividend (%) / Sector
N/A / 0.05
  Dividend Average (%) / Sector
N/A / 16.49
  Dividend Change Average (%) / Sector
N/A / 4.17
Registration Details
X
  Analyze Date 2026-06-06 09:09:24
  Symbol ERAS
  Name ERASCA INC
  Sector Healthcare >> Biotechnology
  Market NASDAQ
  Listed Shares 310.98 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 4,126.77 / 8,857.28
News, Concensus, ...
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 3115 Merryfield Row, San Diego, CA, United States, 92121

Phone: 858 465 6511

Website: https://www.erasca.com

Employees: 103

Sector: Healthcare >> Biotechnology

Description: Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

ME vs SECTOR Healthcare >> Biotechnology

ERAS (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
ERAS
ERAS
USD 11.97 (-9.80%)
+ Watch + Port Chart